Cord blood is frequently described as a convenient source, which undersells it. The cells in a cord blood unit are developmentally distinct from their adult counterparts in ways that change what they can do, and several of those differences are the reason cord blood keeps appearing in cell therapy development rather than merely in banking.
Collected once, non-invasively, and otherwise discarded
Cord blood is recovered from the umbilical cord and placenta after delivery. Collection presents no risk to mother or infant and the material would otherwise be discarded, which is an unusually clean ethical position for a human tissue source and part of why the supply exists at the scale it does.
The constraint is that each collection is a single fixed event. There is no returning to that donor for more, and the total cell number per unit is bounded by what a placenta yields. Programs needing large numbers from one donor are structurally better served by apheresis, discussed in what is apheresis.
What is developmentally different
| Population | How cord blood differs from adult |
|---|---|
| CD34+ haematopoietic stem cells | More naive, with greater proliferative and engraftment potential per cell |
| NK cells | Expand extensively without the exhaustion heavy expansion normally produces; cord blood also carries a CD56 negative CD16 positive population absent from adult blood that can be driven toward mature NK phenotype with IL-15 |
| T cells | Predominantly naive rather than carrying a memory distribution shaped by infection history |
| Regulatory T cells | Expand considerably more readily than their adult counterparts |
The common thread is naivety. These cells have not been through decades of antigen exposure, which makes them more plastic and more tolerant of expansion, and less representative of an adult immune system if that is what you were trying to model.
Related product
CD34+ HSCs. Cord blood-derived CD34+ cells, released against an internal purity specification.
Why it matters for allogeneic development
Expansion capacity is the practical reason cord blood attracts cell therapy interest. A limited starting population that expands enormously without exhausting is a more workable manufacturing proposition than a larger population that degrades as it grows.
Cord blood NK cells illustrate this directly, and the CD19-directed CAR-NK work built on cord blood is the clearest published example of the approach producing meaningful clinical results. That story is set out in the NK cell guide.
Access and equity
One argument for cord blood banking is worth stating because it is genuinely a difference rather than a marketing point. Matched unrelated donor availability is markedly poorer for people of non-European ancestry, since registries are less densely populated with the haplotypes they carry. Cord blood units help close that gap, partly because they are tolerant of a degree of mismatch and partly because banking practices can be directed at under-represented populations. The underlying inheritance argument is in the HLA system.
What to specify
Whether you want whole cord blood or an isolated population, since these are different products. Cell content rather than only purity for isolated fractions. Viability with its timepoint. Donor characterization, particularly HLA type where any immunological work is planned. And format and storage condition.
OrganaBio documents cord blood material through its perinatal program, including CD34+ haematopoietic stem cells, CD56+ NK cells at 1 or 2.5 million cells per vial with viability and purity each listed at 90% or above, CD3+ T cells, and fresh whole cord blood, with high-resolution NGS HLA typing across six genes documented in the donor program.
Frequently asked questions
Why is cord blood used as a cell therapy starting material?
Because the cells are developmentally naive, with greater proliferative and engraftment potential per cell and markedly better tolerance of extensive expansion. A limited starting population that expands without exhausting is a more workable manufacturing proposition than a larger one that degrades as it grows.
How are cord blood NK cells different from adult NK cells?
They expand extensively without the exhaustion heavy expansion normally causes, and cord blood carries a CD56 negative CD16 positive population absent from adult peripheral blood that can be driven toward mature NK phenotype with IL-15.
Is cord blood collection invasive?
No. It is recovered from the umbilical cord and placenta after delivery, presents no risk to mother or infant, and the material would otherwise be discarded.
What is the main limitation of cord blood?
Each collection is a single fixed event with a bounded total cell number, and there is no returning to that donor for more. Programs needing large quantities from one characterized donor are structurally better served by apheresis.
Are cord blood T cells the same as adult T cells?
No. Cord blood T cells are predominantly naive rather than carrying a memory distribution shaped by a lifetime of infection, which suits some protocols precisely and makes them a poor model of an adult immune system.
Why does cord blood matter for donor matching equity?
Matched unrelated donor availability is markedly poorer for people of non-European ancestry because registries are less densely populated with the haplotypes they carry. Cord blood units help close that gap, partly through tolerance of some mismatch and partly through directed banking.
What should I specify when ordering cord blood material?
Whether you need whole cord blood or an isolated population, cell content rather than only purity for isolated fractions, viability with its timepoint, donor characterization including HLA type where immunological work is planned, and format and storage condition.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
